Ganesh Mugundu

1.2k total citations
57 papers, 859 citations indexed

About

Ganesh Mugundu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Ganesh Mugundu has authored 57 papers receiving a total of 859 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 23 papers in Pulmonary and Respiratory Medicine and 19 papers in Molecular Biology. Recurrent topics in Ganesh Mugundu's work include Lung Cancer Treatments and Mutations (11 papers), Cancer Immunotherapy and Biomarkers (11 papers) and PI3K/AKT/mTOR signaling in cancer (9 papers). Ganesh Mugundu is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Cancer Immunotherapy and Biomarkers (11 papers) and PI3K/AKT/mTOR signaling in cancer (9 papers). Ganesh Mugundu collaborates with scholars based in United States, United Kingdom and Canada. Ganesh Mugundu's co-authors include Pankaj B. Desai, Jashvant D. Unadkat, Anshul Gupta, Kenneth E. Thummel, Suzanne F. Jones, David R. Spigel, Gerald S. Falchook, Todd M. Bauer, Sanjeev Kumar and Craig B. Davis and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Ganesh Mugundu

55 papers receiving 843 citations

Peers

Countries citing papers authored by Ganesh Mugundu

Since Specialization

Citations

This map shows the geographic impact of Ganesh Mugundu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ganesh Mugundu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ganesh Mugundu more than expected).

Fields of papers citing papers by Ganesh Mugundu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ganesh Mugundu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ganesh Mugundu. The network helps show where Ganesh Mugundu may publish in the future.

Co-authorship network of co-authors of Ganesh Mugundu

This figure shows the co-authorship network connecting the top 25 collaborators of Ganesh Mugundu. A scholar is included among the top collaborators of Ganesh Mugundu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ganesh Mugundu. Ganesh Mugundu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial 2024 ·Targeted Oncology ·Erika Hamilton, Gerald S. Falchook, Judy S. Wang, Siqing Fu, Amit M. Oza, (unknown), Sanjeev Kumar, Lone H. Ottesen, Ganesh Mugundu, Elza C. de Bruin, Mark J. O’Connor, Suzanne F. Jones, David R. Spigel, Bob T. Li	3
2	Population Pharmacokinetic Modeling of Adavosertib (AZD1775) in Patients with Solid Tumors 2024 ·The Journal of Clinical Pharmacology ·Martin Johnson, Daniel Kaschek, Dana Ghiorghiu, (unknown), (unknown), Henning Schmidt, Ganesh Mugundu	2
3	Open-Label, Multicenter, Phase I Study to Assess Safety and Tolerability of Adavosertib Plus Durvalumab in Patients with Advanced Solid Tumors 2024 ·Targeted Oncology ·Manish R. Patel, Gerald S. Falchook, Judy S. Wang, (unknown), Sanjeev Kumar, (unknown), Ganesh Mugundu, Suzanne F. Jones, David R. Spigel, Erika Hamilton	5
4	A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors 2023 ·Investigational New Drugs ·Gerald S. Falchook, Jasgit C. Sachdev, (unknown), Sanjeev Kumar, Ganesh Mugundu, Suzanne Jenkins, Juliann Chmielecki, Suzanne F. Jones, David R. Spigel, Melissa L. Johnson	17
5	A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors 2023 ·Targeted Oncology ·Todd M. Bauer, Kathleen N. Moore, Janet S. Rader, Fiona Simpkins, Alain C. Mita, J. Thaddeus Beck, Lowell L. Hart, Quincy S. Chu, Amit M. Oza, Anna V. Tinker, (unknown), Sanjeev Kumar, Ganesh Mugundu, Suzanne Jenkins, Juliann Chmielecki, Suzanne F. Jones, David R. Spigel, Siqing Fu	21
6	Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors 2023 ·Cancer Chemotherapy and Pharmacology ·Mats Någård, Mei-Lin Ah-See, James Strauss, Trisha M. Wise‐Draper, Howard Safran, (unknown), William J. Edenfield, Lionel D. Lewis, Lone H. Ottesen, Yan Li, Ganesh Mugundu	1
7	Comprehensive clinical pharmacology characterization of AZD4635 in healthy participants to support dosing considerations 2023 ·British Journal of Clinical Pharmacology ·Ganesh Moorthy, Gayle P. Pouliot, Lorraine Graham, Elizabeth A. Pilling, (unknown), (unknown), (unknown), Yan Li, (unknown), Pablo Forte, Ganesh Mugundu	3
8	Development of a multiscale mechanistic modeling framework integrating differential cellular kinetics of CAR T‐cell subsets and immunophenotypes in cancer patients 2023 ·CPT Pharmacometrics & Systems Pharmacology ·Ahmed Salem, Ganesh Mugundu, Aman P. Singh	12
9	Association between immune-mediated adverse events and efficacy in metastatic non-small-cell lung cancer patients treated with durvalumab and tremelimumab 2022 ·Frontiers in Immunology ·(unknown), (unknown), Harriet M. Kluger, (unknown), Helen Mann, Norah J. Shire, (unknown), Diansong Zhou, Ganesh Mugundu	6
10	Evaluation of Combination Strategies for the A2AR Inhibitor AZD4635 Across Tumor Microenvironment Conditions via a Systems Pharmacology Model 2021 ·Frontiers in Immunology ·Veronika Voronova, Kirill Peskov, Yuri Kosinsky, Gabriel Helmlinger, Lulu Chu, Alexandra Borodovsky, Richard Woessner, Kris F. Sachsenmeier, Wenlin Shao, Rakesh Kumar, Gayle P. Pouliot, Melinda S. Merchant, Holly Kimko, Ganesh Mugundu	13
11	Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors 2020 ·Cancer Chemotherapy and Pharmacology ·Mats Någård, Mei-Lin Ah-See, Karen So, (unknown), Fiona Thistlethwaite, Mariëtte Labots, Patricia Roxburgh, Alain Ravaud, Mario Campone, Liselot Valkenburg‐van Iersel, Lone H. Ottesen, (unknown), Ganesh Mugundu	8
12	Population pharmacokinetic analysis of danvatirsen supporting flat dosing switch 2019 ·Journal of Pharmacokinetics and Pharmacodynamics ·Hongmei Xu, (unknown), Ganesh Mugundu, Martin Scott, Carl Cook, Cecilia Arfvidsson, (unknown), Diansong Zhou, Paul D. Lyne, Nidal Al‐Huniti	11
13	A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma 2018 ·Clinical Cancer Research ·Eduardo Méndez, Cristina P. Rodriguez, Michael Kao, (unknown), Ahmed Diab, R. Alex Harbison, Eric Q. Konnick, Ganesh Mugundu, Rafael Santana-Dávila, Renato Martins, Neal D. Futran, Laura Q.M. Chow	79
14	A multicentre phase II study of AZD1775 plus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer 2017 ·Annals of Oncology ·Kathleen N. Moore, Karen A. Cadoo, Suzanne K. Chambers, Sharad Ghamande, Gottfried E. Konecny, Amit M. Oza, LM Chen, Panagiotis A. Konstantinopoulos, Jayanthi Lea, Daniel L. Spitz, Denise Uyar, Ganesh Mugundu, Naomi Laing, Donald K. Strickland, Suzanne F. Jones, Howard A. Burris, David R. Spigel, Erika Hamilton	2
15	A phase 1b study (SCORES) assessing safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of durvalumab combined with AZD9150 or AZD5069 in patients with advanced solid malignancies and SCCHN 2016 ·Annals of Oncology ·David S. Hong, Gerald S. Falchook, Carl Cook, Wael A. Harb, Paul D. Lyne, Patricia McCoon, Minal Mehta, Pat Mitchell, Ganesh Mugundu, Martin Scott, (unknown)	7
16	A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors 2014 ·Cancer Chemotherapy and Pharmacology ·Joaquı́n Mateo, Jordan Berlin, Johann S. de Bono, Roger B. Cohen, Vicki L. Keedy, Ganesh Mugundu, Lianglin Zhang, Antonello Abbattista, Craig B. Davis, Corrado Gallo Stampino, Hossein Borghaei	30
17	Population Pharmacokinetic-Pharmacodynamic Modelling of 24-h Diastolic Ambulatory Blood Pressure Changes Mediated by Axitinib in Patients with Metastatic Renal Cell Carcinoma 2014 ·Clinical Pharmacokinetics ·Ying Chen, Brian I. Rini, Angel H. Bair, Ganesh Mugundu, Yazdi K. Pithavala	13
18	Quantification of human hepatocyte cytochrome P450 enzymes and transporters induced by HIV protease inhibitors using newly validated LC‐MS/MS cocktail assays and RT‐PCR 2012 ·Biopharmaceutics & Drug Disposition ·Li Liu, Ganesh Mugundu, Brian J. Kirby, Divya Samineni, Pankaj B. Desai, Jashvant D. Unadkat	13
19	Impact of Ritonavir, Atazanavir and Their Combination on the CYP3A4 Induction by Efavirenz in Primary Human Hepatocytes 2010 ·Drug Metabolism Letters ·Ganesh Mugundu, Niresh Hariparsad, Pankaj B. Desai	12
20	Intestinal Human Colon Adenocarcinoma Cell Line LS180 Is an Excellent Model to Study Pregnane X Receptor, but Not Constitutive Androstane Receptor, Mediated CYP3A4 and Multidrug Resistance Transporter 1 Induction: Studies with Anti-Human Immunodeficiency Virus Protease Inhibitors 2008 ·Drug Metabolism and Disposition ·Anshul Gupta, Ganesh Mugundu, Pankaj B. Desai, Kenneth E. Thummel, Jashvant D. Unadkat	96

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact